SLE-肌炎重叠综合征的临床特征与长期结局:对照回顾性队列研究
该单中心回顾性队列纳入855例SLE患者,其中36例(4.2%)合并肌炎。SLE-肌炎重叠组非白种人比例更高、ILD和抗RNP阳性率更高,中位随访22.4年全因死亡率超2倍,肌炎为独立死亡预测因子。
要点
- SLE-肌炎重叠占SLE队列4.2%,以非白种人为主且肾外疾病负担更高。
- 重叠组ILD(13.8% vs 1.2%)与抗RNP阳性率(61.1% vs 20.1%)显著更高。
- 肌炎是SLE患者长期死亡的独立预测因子,ILD与恶性肿瘤亦独立相关。
核心结论
- SLE-肌炎重叠综合征是临床重要亚组,以非白种人为主且肾外疾病负担更高,肌炎是SLE长期死亡的重要预后标志。
研究设计与样本
- 单中心前瞻性维护队列的回顾性分析,纳入1978至2024年随访的855例SLE患者。
- 按是否合并肌炎分为SLE无肌炎组(n=819)与SLE-肌炎重叠组(n=36),比较人口学、临床、血清学及长期结局。
- 生存分析采用Kaplan-Meier法,多因素分析采用Cox比例风险回归。
主要发现
- 肌炎见于4.2%(36/855)的SLE队列。
- 重叠组非裔加勒比裔比例更高(38.9% vs 16.8%;P < 0.001)。
- 重叠组ILD频率更高(13.8% vs 1.2%;P < 0.001),抗RNP阳性率更高(61.1% vs 20.1%;P < 0.001)。
- 中位随访22.4年,重叠组全因死亡率高于无肌炎组(30.5% vs 14%;log-rank P < 0.001)。
- 多因素Cox回归显示肌炎为死亡的独立预测因子,ILD(HR 5.5,95%CI 3.61-9.6;P = 0.004)与恶性肿瘤(HR 3.1,95%CI 2.9-11.6;P < 0.001)亦独立与死亡增加相关。
临床怎么用
- 对SLE患者应评估是否合并肌炎,因其提示更高的长期死亡风险。
- 对SLE-肌炎重叠患者需关注ILD和恶性肿瘤的筛查与监测。
局限性
- 单中心回顾性研究,重叠组样本量小(n=36),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SLE with concurrent myositis has a distinct clinical phenotype, yet its impact on long-term outcomes has been poorly defined. We aimed to determine the risk of mortality, malignancy, and severe renal disease in a large SLE cohort stratified by the presence of myositis. METHODS: We conducted a retrospective analysis of prospectively maintained, single-centre cohort of 855 SLE patients followed between 1978 and 2024. Patients were stratified into two groups: SLE without myositis (n = 819) and SLE-myositis overlap (n = 36). Demographic, clinical, serological, and long-term outcome data were compared. Survival was analysed using the Kaplan-Meier method and multivariable using cox proportional hazards regression. The study was an audit, not requiring formal hospital ethics approval or individual consent, due to the observational retrospective nature of the study using de-identified data-no individualized or identifiable data are presented in this study. RESULTS: Myositis was identified in 4.2% (36/855) of the SLE cohort. The SLE-myositis overlap group was characterized by a higher proportion of patients of Afro-Caribbean ethnicity (38.9% vs 16.8%; P < 0.001) a greater frequency of interstitial lung disease (ILD) (13.8% vs 1.2%; P < 0.001) and higher rates of anti-RNP positivity (61.1% vs 20.1%; P < 0.001). All-cause mortality over a median follow-up of 22.4 years was over 2-fold higher in the SLE-myositis group (30.5% vs 14%; log-rank P < 0.001). Multivariable Cox regression confirmed that the presence of myositis was an independent predictor of mortality. ILD (hazard ratio [HR] 5.5, 95% CI 3.61-9.6; P = 0.004) and malignancy (HR 3.1, 95% CI 2.9-11.6; P < 0.001) were also independently associated with increased mortality. CONCLUSION: SLE-myositis overlap syndrome represents a clinically important subgroup characterized by a predominance of non-Caucasian patients and a higher burden of extra-renal disease. The presence of myositis is an important prognostic marker associated with increased long-term mortality in patients with SLE.
引用
- Uzun GS, Isenberg D. Clinical characteristics and long-term outcomes in SLE-myositis overlap syndrome: a controlled retrospective cohort study. Rheumatology (Oxford). 2026. PMID: 42671358. doi:10.1093/rheumatology/keag452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。